RUO education · Evidence first
A field guide to selected synthetic records, organized around identity, evidence quality, and uncertainty. The groupings below are reading guides only: no use stack, sequence, amount, route, timing, outcome promise, or human or veterinary use is provided.
Suggested reading paths · TL;DR
These groupings make a friend-facing conversation easier to scan. They are not recommendations to combine, buy, or use the records.
TL;DR: Compare three different literatures: membrane biology, mitochondrial-derived peptide research, and coenzyme biochemistry. The grouping does not establish a system, sequence, compatibility, or additive outcome.
TL;DR: Compare exact identity, study design, and formulation limits. Similar placement in a guide does not establish a shared purpose, outcome, or reason to combine the records.
TL;DR: Every name on this page resolves through an exact active stable ID. Archived records and evidence about related materials do not silently transfer into the current catalog.
Current development policy · keystone-ruo-local-test-v1
Research Use Only. Not for human or veterinary use. This synthetic local/test environment does not authorize clinical, diagnostic, therapeutic, food, household, or veterinary use.
Keystone does not present these records for diagnosis, treatment, mitigation, prevention, dosing, efficacy, or any therapeutic purpose. The catalog does not recommend a product based on a condition, symptom, goal, or intended use.
A synthetic identity can acknowledge this exact version during onboarding. A fresh, unchecked acknowledgement is also required for every test checkout.
A three-part reading method
The useful discipline is to preserve evidence tiers instead of flattening laboratory findings, small studies, anecdotes, and completed controlled trials into one story.
Start with the exact molecule, formulation, and stable registry record. Similar names and related compounds are not substitutes.
Separate laboratory work, animal models, small human studies, registered trials, completed results, and informal reports.
Do not transfer a finding to a mixture, a different formulation, another outcome, or an RUO material the study did not examine.
Mitochondrial research lens
The records below are presented independently and alphabetically. Their order does not establish combined use, sequence, timing, compatibility, or an additive outcome.
The literature examines elamipretide in relation to cardiolipin and inner mitochondrial membrane biology. FDA status for a specific prescription product and narrow labeled indication does not transfer to this synthetic RUO record or any other purpose.
MOTS-C is described in the literature as a mitochondrial-derived peptide. Human investigation is ongoing; a registered study is not a reported result.
NAD+ is a coenzyme, not a peptide. It appears here as a related biochemical research topic, not because it shares the same molecular class or establishes a protocol with the other records.
Identity and evidence lens
These records do not form a single scientific class. Similar online placement does not establish a shared intended use, mechanism, compatibility, or outcome.
Epithalon should not be conflated with Epithalamin, an older extract and a different material. Evidence tied to one name or formulation does not transfer to the other.
Evidence about a constituent does not transfer automatically to the combined record. The exact formulation and stable registry identity bound every inference.
N-acetyl-selank is a distinct current variant. Evidence about legacy Selank does not transfer automatically to this record.
Reference trail · Reviewed August 16, 2026
Catalog identity: Keystone Catalog v2, effective 2026-08-23T21:44:57Z, SHA-256 467a807e49dd863a09ce277b5f9010c157d5d4a38e9b81e32d294135a3d90f43.
Regulatory status: FDA, “Drug Trials Snapshots: Forzinity,” approval date September 19, 2025; FDA, “Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.”
Active research record: ClinicalTrials.gov NCT07505745. Registration describes a study; it does not supply completed efficacy or safety results.
Variant boundary: PubMed PMID 25176261 concerns Selank, not N-acetyl-selank; it is cited here only to show why evidence cannot be transferred across variants.
Reference identifiers are provided for independent verification, not as an endorsement. Status and evidence can change after the review date.